IL2 and neoplasm: The use of these drugs not only negates the side effects of a treatment with rapamycin—namely immune suppression due to inhibition of the response to IL-2 [59], thus blocking the activation and proliferation of T and B cells—but, in fact, synergizes with the anti-tumour activity of the OV and the encoded therapeutic transgene.